

References

[Copies of references marked with an asterisk are provided as part of this briefing document].

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington, DC;1994.

*Bachmann G, Bancroft J, Braunstein G, et al. Female androgen insufficiency: the Princeton consensus statement on definition, classification, and assessment. *Fert Steril* 2002;77:660-665.

Bancroft J, Loftus MA, Long JS. Distress about sex: a national survey of women in heterosexual relationships. *Arch Sex Behav* 2003;32:193-208.

Barrett-Connor E, Timmons C, Yound R, Wiita B, and the Estratest Working Group. Interim safety analysis of a two-years study comparing oral estrogen-androgen and conjugated estrogens in surgically menopausal women. *J Womens Health* 1996;5:593-602.

*Basaria S, Dobs AS. Safety and adverse effects of androgens: how to counsel patients. *Mayo Clin Proc* 2004;79(suppl):S25-S32.

Basaria S, Nguyen T, Rosenson RS, Dobs AS. Effect of methyl testosterone administration on plasma viscosity in postmenopausal women. *Clin Endocrinol (Oxf)* 2002;57:209-214.

Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. *Lancet* 2003; 362: 419-427.

*Braunstein GD. Androgen insufficiency in women: summary of critical issues. *Fertil Steril* 2002; 77: S94-S99.

*Burger HG. Androgen production in women. *Fertil Steril* 2002; 77: S3-S5.

*Cameron DR, Braunstein GD. Androgen replacement therapy in women. *Fert Steril* 2004;82:273-289.

Dauvois S, Li SM, Martel C, Labrie F. Inhibitory effect of androgens on DMBA-induced mammary carcinoma in the rat. *Breast Cancer Res Treat* 1989;14:299-306.

Dauvois S, Geng Cs, Levesque C, Merand Y, Labrie F. Additive inhibitory effects of an androgen and the antiestrogen EM-170 on estradiol-stimulated growth of human ZR-75-1 tumors in athymic mice. *Cancer Res* 1991;51:3131-3135.

Davis SR, McCloud P, Strauss BJ, Burger H. Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. *Maturitas* 1995;21:227-236.

*Derogatis L, Rust J, Golombok S, et al. Validation of the Profile of Female Sexual Function (PFSF) in surgically and naturally menopausal women. *J Sex Marital Ther* 2004; 30:25-36.

Derogatis, L.R. The Derogatis Interview for Sexual Functioning (DISF/DISF-R): An introductory report. *J Sex Marital Ther* 1997;23:291-304.

*Dimitrakakis C, Jones RA, Liu A, Bondy CA. Breast cancer incidence in postmenopausal women using testosterone in addition to usual hormone therapy. *Menopause* 2004;11:531-535.

*Dimitrakakis C, Zhou J, Wang J et al. A physiological role for testosterone in limiting estrogenic stimulation of the breast. *Menopause* 2003;10:292-298.

Dunn KM, Croft PR, Hackett GI. Sexual problems: a study of the prevalence and need for health care in the general population. *Fam Pract* 1998;15:519-24.

The Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. *J Natl Cancer Inst* 2002;94:606-616.

Fugl-Meyer KS, Fugl-Meyer AR. Sexual disabilities, problems, and satisfaction in 18-74 year old Swedes. *Scand J Sexol* 1999;3:79-105.

Gammon MD, Thompson WD. Polycystic ovaries and the risk of breast cancer. *Am J Epidemiol* 1991;134:818-824.

Geiss IM, Umek WH, Dungl A, Sam C, Riss P, Hanzal E. Prevalence of female sexual dysfunction in gynecologic and urogynecologic patients according to the international consensus classification. *Urology* 2003;62:514-8.

Graziottin A, Koochaki PE. Distress associated with low sexual desire in women in four European countries: Germany, France, UK, & Italy. Paper presented at: Second International Consultation on Erectile and Sexual Dysfunctions; June 28-July 3, 2003; Paris, France.

Isaksson E, von Schoultz E, Odlind V et al. Effects of oral contraceptives on breast epithelial proliferation. *Breast Cancer Res. Treat* 2001;65:163-9.

Jayo MJ, Register TC, Hughes CL, Blas-Machado U, Sulistiawati E, Borgerink H, Johnson CS. Effects of an oral contraceptive combination with or without androgen on mammary tissues: a study in rats. *J Soc Gynecol Invest* 2000;7:257-265.

Judd HL, Lucas WE, Yen SC. Effect of oophorectomy on circulating testosterone and androstenedione levels in patients with endometrial cancer. *Am J Obstet Gynecol* 1974;118:793-8.

Hughes CL Jr, Wall LL, Creasman WT. Reproductive hormone levels in gynecologic oncology patients undergoing surgical castration after spontaneous menopause. *Gynecol Oncol* 1991;40:42-5.

Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States. *JAMA* 1999;281:537-44.

Leiblum S, Koochaki P. Poster presented at the 7th Congress of the European Federation of Sexology, Brighton, UK, May 12-16, 2004.

*Leiblum SR, Koochaki PE, Rosen RC. Self-reported distress associated with decreased interest in sex in women. Paper presented at: Second International Consultation on Erectile and Sexual Dysfunctions; June 28-July 3, 2003; Paris, France.

Lobo RA. Androgens in postmenopausal women: production, possible role, and replacement options. *Obstetric Gynecol Surv* 2001;56:361-376.

Lobo RA, Rosen RC, Yang HM, Block B, Van Der Hoop RG. Comparative effects of oral esterified estrogens with and without methyltestosterone on endocrine profiles and dimensions of sexual function in postmenopausal women with hypoactive sexual desire. *Fertil Steril* 2003;79:1341-1352.

Lorenzo EM. Familial study of hirsutism. *J Clin Endocrinol* 1970; 31:556-64.

Mattson Jack Epidemiologic Data.

Mazer N, Shifren J. Transdermal testosterone for women; a new physiological approach for androgen therapy. *Obstet Gynecol Surv* 2003;58:489-500.

*McHorney CA, Rust J, Golombok S, et al. The Profile of Female Sexual Function (PFSF)[®]: a patient-based, international, psychometric instrument for the assessment of hypoactive sexual desire in oophorectomized women. *Menopause*. 2004;11:474-483.

Najman JM, Dunne MP, Boyle FM, Cook MD, Purdie DM. Sexual dysfunction in the Australian population. *Aust Fam Physician* 2003;32:951-4.

National Disease and Therapeutic Index, IMS Health, 2003.

Nunnally JC, Bernstein IH. Psychometric Theory. (3rd ed.). 1994 New York: McGraw-Hill.

Osborn M, Hawton K, Gath D. Sexual dysfunction among middle-aged women in the community. *Br Med J* 1988;296:959-62.

Palatsi R, Hirvensalo E, Liukko P, Malmiharju T, Mattila L, Riihilauma P, et al. Serum total and unbound testosterone and sex hormone binding globulin (SHBG) in female acne patients treated with two different oral contraceptives. *Acta Derm Vernereol (Stockh)*, 1984; 64:517-23.

Ries LAB, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, Mariotto A, Feuer EJ, Edwards BK (eds.). SEER Cancer Statistics Review, 1975-2001, National Cancer Institute. Bethesda, MD, <http://seer.cancer.gov/csr/1975-2001/>, 2004.

Richters J, Grulich AE, de Visser RO, Smith AMA, Rissel CE. Sex in Australia: sexual difficulties in a representative sample of adults. *Aust N Z J Public Health* 2003;27:164-70.

Sarrel PM, Whitehead MI. Sex and menopause: defining the issues. *Maturitas* 1985;7:217-224.

Sherwin BB, Gelfand MM. The role of androgen in the maintenance of sexual functioning in oophorectomized women. *Psychosomatic Med* 1987;49:397-409.

*Shifren JL, Braunstein GD, Simon JA, Casson PR, Buster JE, Redmond GP, et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. *N Engl J Med* 2000;343:682-8.

Sloan J, Symonds T, Vargas-Chanes D, Fridley B. Practical guidelines for assessing the clinical significance of health-related quality of life changes within clinical trials. *Drug Information Journal* 2003;37(1):23-31.

*Somboonporn W, Davis SR. Testosterone effects on the breast: implications for testosterone therapy for women. *Endocr Rev* 2004;25:374-88.

Van Kesteren PJ, Asscheman H, Megens JA, Gooren LJ. Mortality and morbidity in transsexual subjects treated with cross-sex hormones. *Clin Endocrinol (Oxf)* 1997;47:337-342.

WHI Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. *JAMA* 2004;291:1701-1712.

*Wu FCW, von Eckardstein A. Androgens and coronary artery disease. *Endo Rev* 2003;24:183-217.